Breaking Finance News

Dynavax Technologies Corporation (NASDAQ:DVAX) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) to Hold in a statement released on 11/28/2016.

Boasting a price of $5.00, Dynavax Technologies Corporation (NASDAQ:DVAX) traded -8.00% lower on the day. With the last close down -64.72% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Dynavax Technologies Corporation has recorded a 50-day average of $8.70 and a two hundred day average of $13.04. Volume of trade was down over the average, with 1,651,861 shares of DVAX changing hands under the typical 2,353,730

Performance Chart

Dynavax Technologies Corporation (NASDAQ:DVAX)

With a total market value of $0, Dynavax Technologies Corporation has with a one year low of $3.20 and a one year high of $29.86 .

A total of 4 analysts have released a research note on DVAX. One analyst rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $43.75.

More About Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.